Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms
Open accessThe DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Abstract
The incidence of chronic kidney disease (CKD) is increasing worldwide, with more than 26 million people suffering from CKD in the United States alone. More patients with CKD die of cardiovascular complications than progress to dialysis. Over 80% of CKD patients have hypertension, which is associated with increased risk of cardiovascular morbidity and mortality. Another common, perhaps underappreciated, feature of CKD is an overactive sympathetic nervous system. This elevation in sympathetic nerve activity (SNA) not only contributes to hypertension but also plays a detrimental role in the progression of CKD independent of any increase in blood pressure. Indeed, high SNA is associated with poor prognosis and increased cardiovascular morbidity and mortality independent of its effect on blood pressure. This brief review will discuss some of the consequences of sympathetic overactivity and highlight some of the potential pathways contributing to chronically elevated SNA in CKD. Mechanisms leading to chronic sympathoexcitation in CKD are complex, multifactorial and to date, not completely understood. Identification of the mechanisms and/or signals leading to sympathetic overactivity in CKD are crucial for development of effective therapeutic targets to reduce the increased cardiovascular risk in this patient group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Original record of muscle sympathetic nerve activity (MSNA) in a normal subject and a renal failure patient on hemodialysis, demonstrating significantly greater resting MSNA in the dialysis patient. The bottom two panels display a portion of the neurogram and simultaneous electrocardiogram from the patient on hemodialysis showing that the renal failure patient has a burst of MSNA with every cardiac cycle. (Modified from Converse et al. [11] with permission).](https://figures.cochat.ai/paper-figures/c29f315edad14e6d80676416128a09dc/sympathetic-overactivity-in-chronic-kidney-disease-consequences-and-mechanisms-figure-1.jpg)
![Figure 2 Muscle sympathetic nerve activity (MSNA) expressed as burst frequency (bursts (bs)/min, A) and burst incidence (bs/100 heartbeats (hb), B) in subjects grouped according to their estimated glomerular filtration rate (eGFR), with the highest quartile of eGFR in group I and lowest quartile of eGFR in group IV. With decreasing eGFR, there is a significant and progressive increase in resting MSNA in chronic kidney disease (CKD) patients. * p < 0.05 significant difference between quartiles. (From Grassi et al. [13] with permission).](https://figures.cochat.ai/paper-figures/b4ac89c6b0474f7ca430dc2de3b4c6dc/sympathetic-overactivity-in-chronic-kidney-disease-consequences-and-mechanisms-figure-2.jpg)
![Figure 3 Mean arterial pressure (MAP) responses during 8-h continuous systemic infusion of the nitric oxide synthase (NOS) inhibitor l-nitroarginine methyl ester (l-NAME) in rats with sympathectomy (open circles) and without sympathectomy (closed circles). Although no difference was observed in the initial increase in MAP (removal of endothelium-mediated dilation), sympathectomy attenuated the sustained hypertensive response to l-NAME, demonstrating a sympathetic contribution to the blood pressure raising effects of systemic NOS inhibition. * p < 0.05 vs. control. (From Sander et al. [75] with permission).](https://figures.cochat.ai/paper-figures/c4fa82d6798d4656876e51594ce8db56/sympathetic-overactivity-in-chronic-kidney-disease-consequences-and-mechanisms-figure-3.jpg)
![Figure 4 Average mean arterial pressure, heart rate, and renal sympathetic nerve activity during continuous systemic infusion of asymmetric dimethylarginine (ADMA; an endogenous NOS inhibitor) in baroreceptor-intact (A) and baroreceptor-denervated animals (B). In comparison with barointact animals, barodenervated animals show a significant increase in renal SNA indicating frank sympathoexcitation in response to systemic ADMA infusion. * p < 0.05 vs. baseline; † p < 0.05 vs. baroreceptor intact. (From Augutyniak et al. [87] with permission.)](https://figures.cochat.ai/paper-figures/c6752938f9484a64b8856be4cf6b53c4/sympathetic-overactivity-in-chronic-kidney-disease-consequences-and-mechanisms-figure-4.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Elevated sympathetic nerve activity is a hallmark of CKD104 that is evident even in the early stages of the disease and correlates inversely with estimated glomerular filtration rate (eGFR) and disease progression105.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [104]
In the citing paper
“The occur-rence of increased SNS activity in hypertension and CKD is well established83,162.”
From The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease (2018) · cites this paper as [162]
In the citing paper
“Modulation of the gut microbiota reduces systemic inflammation and SNS activity, both of which contribute to hypertension and CKD80,162,208.”
From The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease (2018) · cites this paper as [162]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895 · cited 1×
“More than 26 million people in the United States suffer from chronic kidney disease (CKD) with thousands of new cases diagnosed each year [1].”
Background(2010) · The Lancet · doi:10.1016/s0140-6736(10)60674-5 · Cited by 4,200 · cited 1×
“Moderate to severe CKD (stage 3–5) is associated with a significantly higher risk of cardiovascular (CV) morbidity and mortality [4,5].”
BackgroundAngiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells.
Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., & Alexander, R. W. (1994) · Circulation Research · doi:10.1161/01.res.74.6.1141 · Cited by 2,735
A Controlled Trial of Renal Denervation for Resistant Hypertension
Bhatt, D. L., Kandzari, D. E., O'Neill, W. W., D'Agostino, R., Flack, J. M., Katzen, B. T., Leon, M. B., Liu, M., Mauri, L., Negoita, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402670 · Cited by 2,186
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Physiological aspects of primary hypertension.
Folkow, B. (1982) · Physiological Reviews · doi:10.1152/physrev.1982.62.2.347 · Cited by 1,768
Böger, R. H., Bode-Böger, S. M., Szuba, A., Tsao, P. S., Chan, J. R., Tangphao, O., Blaschke, T. F., & Cooke, J. P. (1998) · Circulation · doi:10.1161/01.cir.98.18.1842 · Cited by 1,181
Cited by
Items 101–167 of 167
Yao, J., Sprick, J. D., Jeong, J., Park, J., & Reiter, D. A. (2023) · Microvascular Research · doi:10.1016/j.mvr.2023.104624 · Cited by 4
Deußing, K., Wendt, R. T., Burger, R., Gollasch, M., & Beige, J. (2019) · Blood Purification · doi:10.1159/000504525 · Cited by 3
Nolde, J. M., Lugo‐Gavidia, L. M., Carnagarin, R., Azzam, O., Kiuchi, M. G., Mian, A. S., & Schlaich, M. P. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.105087 · Cited by 3
Lo, K. B., Iskarous, K., & Sankaranarayanan, R. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.002 · Cited by 3
Costa, M. D., Redline, S. S., Bansal, N., Heckbert, S. R., & Goldberger, A. L. (2025) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00091.2025 · Cited by 3
Renal Denervation Improves Uremic Cardiomyopathy in Rats With Chronic Kidney Disease
Markwirth, P., Selejan, S., Hohl, M., Schunk, S. J., Müller, A., Wagenpfeil, S., Wagmann, L., Kahles, F., Tokcan, M., Therre, M., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038785 · Cited by 2
“8 In fact, this overactivity of the sympathetic nervous sys-tem is thought to contribute to cardiovascular mortality in CKD. 9 Renal denervation (RDN) reduces not only renal sympathetic tone, but also central sympathetic activity.”
Future perspective on chronic kidney disease management
Qiu, X., Ding, X., Liu, H., & Li, Q. (2025) · Journal of Anesthesia and Translational Medicine · doi:10.1016/j.jatmed.2025.06.002 · Cited by 2
Seiman, D. M. D., Bucuras, P., Kundnani, N. R., Sharma, A., Rada, M., Albulescu, N., Buciu, V., Movila, D., Velimirovici, D. E., & Dinu, A. R. (2025) · Healthcare · doi:10.3390/healthcare13212671 · Cited by 2
“Chronic activation of the hypothalamic–pituitary–adrenal axis and sympathetic nervous system can promote glomerular hypertension, systemic inflammation, and endothelial dysfunction, all of which accelerate nephron loss [51–53].”
Physiology of Blood Pressure Regulation and Pathophysiology of Hypertension
Elliott, J. (2020) · Springer eBooks · doi:10.1007/978-3-030-33020-0_1 · Cited by 3
A Need to Preserve Ejection Fraction during Heart Failure
Akinterinwa, O. E., Singh, M., Vemuri, S. R., & Tyagi, S. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168780 · Cited by 2
Malik, R., Sikander, S., Qadir, J., Ahmed, M., Habib, M. K., & Mustafa, H. A. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i2.753 · Cited by 2
Norepinephrine Turnover in the Left Ventricle of Subtotally Nephrectomized Rats
Nalos, L., Švíglerová, J., Rajdl, D., Jedlička, J., Dejmek, J., Štengl, M., & Kuncová, J. (2019) · Physiological Research · doi:10.33549/physiolres.934354 · Cited by 2
Angiotensin 1–7 and the Sympathetic Nervous System in Hypertensive Kidney Disease
Tsuda, K. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz114 · Cited by 2
Nishihara, M., Shinohara, K., Ikeda, S., Akahoshi, T., & Tsutsui, H. (2024) · Journal of Intensive Care · doi:10.1186/s40560-024-00742-2 · Cited by 3
“In CKD patients, cardiovascular events are strongly associated with increased sympathetic activity [31–33].”
BackgroundEnache, I. I., Manea, M. M., Tuță, S., & Sîrbu, C. A. (2025) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2025.108981 · Cited by 2
“Exaggerated sympathetic nervous system activation can occur even in the early stages of kidney dysfunction [145].”
Meng, S., He, H., Li, D., & Li, N. (2025) · Cardiology Discovery · doi:10.1097/cd9.0000000000000167 · Cited by 1
Ameer, O. Z. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1808065 · Cited by 1
“Reactive oxygen species in central autonomic regions also facilitate sympatho-excitation, with effects at both vascular and neural levels (Hirooka, 2011; Mancia and Grassi, 2014; Kaur et al., 2017; Ameer, 2022; Sabino-Carvalho et al., 2024).”
Goldman, J. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-83082-3_7 · Cited by 1
Renin-Angiotensin System in Chronic Kidney Disease: Implications in Stroke Outcome
Datta, A., Sarmah, D., Ghosh, B., Chaudhary, A., Sehgal, K., Ghosh, D., Karande, M., Jadhav, P., Sahu, S., Sarkar, A., et al. (2023) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-23621-1_14 · Cited by 1
Intradialytic Hypotension During Heamodyalysis
Rehman, Z. U., Mohammad, N., Khan, M. W., Muhammad, S., Khan, M. U., Khan, T. U., & Akhunzada, M. I. (2023) · Journal of Gandhara Medical and Dental Science · doi:10.37762/jgmds.10-2.434 · Cited by 1
“These ndings are in consistent with other studies.(7,8,910) Furthermore, Intradialysis hypotension has appeared more frequent than intradialysis hypertension.”
ResultEvangelista, F. C. G. (2023) · Ensaios e Ciência C Biológicas Agrárias e da Saúde · doi:10.17921/1415-6938.2023v27n2p213-221 · Cited by 4
The denervation or activation of renal sympathetic nerve and renal blood flow
Kharazmi, F., Hosseini-Dastgerdi, H., Pourshanazari, A., & Nematbakhsh, M. (2023) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_216_23 · Cited by 4
“[133] The glomerular microvasculature becomes more constricted as a result of NO production inhibition and proximal tubular reabsorption decreases.”
BackgroundIs mild dehydration a risk for progression of childhood chronic kidney disease?
Page, A. K. L., Johnson, E. C., & Greenberg, J. H. (2024) · Pediatric Nephrology · doi:10.1007/s00467-024-06332-6 · Cited by 3
“Further study is required to understand if mild dehydration can augment local intrarenal sympathetic nerve activity that can accelerate CKD progression [74].”
BackgroundRoxadustat Has Beneficial Effects on the Vascular Tone of the Rat Thoracic Aorta
Nakagawa, K., Oshiba, Y., Sukita, R., Hosomi, A., Tawa, M., & Ohkita, M. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001697 · Cited by 1
Cabral, P., Silva, G. B., Baigorria, S. T., Juncos, L. I., Ajayi, E. I. O., & Garcia, N. H. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.21.243 · Cited by 1
“This pathological condition is characterized by sodium retention as a consequence of enhanced sympathetic activity [33] and increase synthesis of intrarenal angiotensin II synthesis [34], endothelin-1 [35], and 8-iso-PGF2α, all of which stimulate sodium reabsorption.”
BackgroundPathophysiology and Mechanisms of Hypertension (Asian Context)
MERCADO-ASIS, L. B. (2022) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-030-95734-6_2 · Cited by 1
Rezende, R. A. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2018.tde-12062018-124609
“Os principais são a hiperatividade simpática, que é detectada em fases precoces da doença e se acentua com sua progressão; a hiperatividade do SRAA, que caminha ao lado da ativação simpática, se manifesta por altas concentrações de angiotensina II e cujo bloqueio do sistema é indicação para retardar a progressão; a re…”
BackgroundIs chronic kidney disease keeping the heart up all night?
Shen, J. I., & Norris, K. C. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13439
Home blood pressure on winter mornings could be exaggerated: A comparison with summer mornings
Mizoguchi, T., Sugiura, T., Dohi, Y., Takase, H., Yamashita, S., Murai, S., Seo, Y., & Ohte, N. (2020) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2020.1779283 · Cited by 1
Почки и вегетативная дисфункция у детей и подростков (часть I)
Вакуленко, Л. І. (2020) · KIDNEYS · doi:10.22141/2307-1257.9.2.2020.203408
Vučić, D., Miškić, B., Leko, N., Praveček, M. K., Gabaldo, K., Lukenda, K. C., & Bosnić, Z. (2021) · Medicina Fluminensis · doi:10.21860/medflum2021_371659
Olkhovska, V. (2021) · Clinical and Preventive Medicine · doi:10.31612/2616-4868.3(17).2021.04
On the sustainable development of small island developing nations in the Pacific region
Eddington, I. (2006) · University of Southern Queensland ePrints (University of Southern Queensland)
Bae, S. R., Goodson, D. A., Vargas, C. R., Kim, T. Y., Begue, G., Delgado, C., Robinson‐Cohen, C., Gamboa, J. L., Himmelfarb, J., de Boer, I. H., et al. (2022) · medRxiv · doi:10.1101/2022.03.30.22273207
“type II muscle fibers(5), metabolic acidosis(6,7), increased sympathetic tone(8), inflammation(9),”
BackgroundSGLT2 inhibitors: suggestions from the amphibian world
Michelassi, S. (2022) · Giornale di Clinica Nefrologica e Dialisi · doi:10.33393/gcnd.2022.2423
Wrzosek, M., Hojka-Osińska, A., Klimczak‐Tomaniak, D., Żarek-Starzewska, A., Dyrla, W., Rostek-Bogacka, M., Wróblewski, M., Kuch, M., & Kucia, M. (2022) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/157303
Patil, A. N., Patil, K. B., Prasad, N., & Dighe, T. A. (2024) · Journal of the Scientific Society · doi:10.4103/jss.jss_164_23
Renal denervation benefits in chronic kidney disease: An updated review
Habas, E. M., Alarbi, K. M. S., Habas, A. M., Baghi, M. A. M., Habas, E., Rayani, A., Said, A., Farfar, K., Errayes, A., Alfitori, G. B., et al. (2024) · Yemen Journal of Medicine · doi:10.18231/j.yjom.2024.004
Sympathetic transduction to blood pressure in patients with chronic kidney disease
Kissell, C. E., Young, B. E., Kaur, J., Taherzadeh, Z., Mohan, P. C., Vianna, L. C., & Fadel, P. J. (2024) · Clinical Autonomic Research · doi:10.1007/s10286-024-01084-7
“An overactive sympathetic nervous system may also contribute to augmented cardiovascular risk in CKD [20]; an effect that may be independent of elevated blood pressure (BP) [9].”
Self-citationStrukturelle Veränderungen des Herzens bei Patienten mit chronischer Nierenerkrankung
Kocaman, H. (2025) · Nephrologie aktuell · doi:10.1055/a-2497-1771
Treatment of Hypertension in Chronic Kidney Disease
Redón, J. (2025) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-81292-7_15
Lapsiwala, B. J., Nathani, P. S., Bhalodia, A. R., Rangan, A., Khan, F., Rajpopat, P. B., Vaghani, U., Kanagala, S. G., Bali, A., Naik, R., et al. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.05.004 · Cited by 1
Hemodiyalize Bağlı Gelişen Kardiyovasküler Disfonksiyona Yönelik Egzersiz Yaklaşımları
Özdemir, C., & Barğı, G. (2025) · Izmir Democracy University Health Sciences Journal · doi:10.52538/iduhes.1587695 · Cited by 1
Avramovski, P. J., Avramovska, M., Nikleski, Z., Todorovska, L., Sotiroski, K., Siklovska, V., Trajcevska, I., & Vasilevski, S. (2025) · Dubai Medical Journal · doi:10.18502/dmj.v8i2.19005 · Cited by 1
Hemodialysis removes protective metabolites and disrupts mitochondrial function
Peris‐Fernández, M., Roca, M., Viejo-Boyano, I., Soldevila-Orient, A., Devesa-Such, R. J., Pérez, P. S., & Jaras, J. H. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf145
Hidden Impacts of Peritoneal Dialysis on the Endocrine System
Ueno, H., Ueta, Y., Koga, J., Maruyama, T., Miyamoto, T., & Kataoka, M. (2025) · Life · doi:10.3390/life15101588
“Heightened sympathetic activity is frequently observed in patients with chronic kidney disease (CKD) [31].”
Blood Pressure Management in Dialysis: A Comparative Review of Hemodialysis and Peritoneal Dialysis
Jonny, J., Pranidya, N. P., & Sugiharta, A. J. (2025) · Current Hypertension Reviews · doi:10.2174/0115734021408764250929235308
“Elevated muscle sympathetic nerve activity is evident even in the early stages of CKD and persists in ESRD, often independent of volume status or glomerular filtration rate [41-43].”
Cardiorenal Syndrome and Autonomic Overactivity
Mannozzi, J. T., Duncan, D., Johnson, J. D., Kohrman, A., & O’Leary, D. S. (2025) · Biomedicines · doi:10.3390/biomedicines13122947
“That said, once activated, these afferents have been shown to elicit robust sympathetically mediated alterations in blood pressure, heart rate, and vascular function [32,38,40,69,70].”
Nishihara, M., Shinohara, K., Ikeda, S., Akahoshi, T., & Tsutsui, H. (2024) · Figshare · doi:10.6084/m9.figshare.26944923
Nishihara, M., Shinohara, K., Ikeda, S., Akahoshi, T., & Tsutsui, H. (2024) · Figshare · doi:10.6084/m9.figshare.26944920
Management of Hypertension in Patients Undergoing Peritoneal Dialysis: A Narrative Review
Ramlal, A. A., Naimat, A., Ramakrishnan, A., Pattathil, M., Shahbaz, T., Tariq, Y., Bodige, M., Irum, Z., Dontul, V., Ali, A., et al. (2026) · Cureus · doi:10.7759/cureus.105215
“Its loss in PD patients results in greater uremic toxin accumulation, poor sodium handling, and activation of both RAAS and SNS, which can lead to hypertension [17].”
The fibroblast growth factor-Klotho endocrine system in health and disease
Makoto, K.-O. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13683-2.00034-7
Zelniker, T. A., Paschen, C., Mann, C., Eigner, M., Hafner-Gießauf, H., Kletzmayr, J., Lorenz, M., Ludvik, B. H., Stulnig, T. M., Waller, I., et al. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag104 · Cited by 1
Devi, R., Singh, N., Rawat, B., & Saini, K. (2026) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v16i5.7760
“This explains why sudden cardiac mortality is so common in people with CKD 24,25 .”
Post-exercise heart rate recovery across stages of non-dialysis chronic kidney disease
Acar, E. A., Toraman, A., Cetintepe, L., Özlek, E., Tıkız, H., & Kürşat, S. (2026) · Journal of Human Hypertension · doi:10.1038/s41371-026-01161-6 · Cited by 1
“Mechanistically, elements such as renal afferent signaling, stimulation of the renin – angiotensin – aldosterone sys-tem, in fl ammation and oxidative stress are believed to contribute to persistent sympathetic overactivity [4].”
Merlino, L., Rainone, F., Tollit, J., Kalra, M. J., Williford, S., Rusconi, F., Battini, G. G., Dunne, R. A., Kalra, P. A., & Chrysochou, C. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag174
“In young adults with CKD, ischemic heart disease codes often reflect demand ischemia, autonomic instability, or microvascular dysfunction rather than premature obstructive coronary disease [ 22–24 ].”
Bhunyakarnjanarat, T., Leelahavanichkul, A., & Chancharoenthana, W. (2026) · World Journal of Nephrology · doi:10.5527/wjn.v15.i2.118565
Michna, M., Burgetová, R., Kremeňová, K., Burgetová, A., Krásenský, J., Lukavský, J., Szonowská, B., Rychlik, I., Malikova, H., & Malík, J. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1885904 · Cited by 1
“Several metabolic factors, including uremic toxins, altered plasma osmolarity (9–12), chronic low-grade inflammation (13) and endocrine changes (14, 15) also influence the development of cognitive deficit.”
Pathophysiology of Hypertension in Chronic Kidney Disease: Role of the Renin-Angiotensin System
Anyfanti, P. (2026) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-032-29564-4_2
Sex-specific association between obesity and sympathetic nerve activity in HFpEF
Washio, T., Hissen, S. L., Akins, J. D., Takeda, R., D’Souza, A. W., MacNamara, J. P., Sarma, S., Trott, D. W., Lutz, K. C., Hearon, C. M., et al. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00214.2026
Self-citationChronic Kidney Disease-Associated Cardiomyopathy: Mechanisms and Therapeutic Strategies
Grigoriou, K., Lamprou, V., Chatzichidiroglou, A., Theofilis, P., Iliakis, P., Apostolos, A., Ktenopoulos, N., Karagiannidis, E., Antoniadis, A. P., Fragakis, N., et al. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm51534
Epidural Anesthesia/Block for Chronic Kidney Disease and Chronic Heart Failure
Qifang, L. (2026) · Springer eBooks · doi:10.1007/978-3-032-25214-2_25
Cardiovascular–kidney–metabolic syndrome as a mitochondrial systems disorder
Shen, L., Abel, E. D., Arany, Z. P., Baur, J. A., Pei, L., & Suszták, K. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01127-4 · Cited by 1
Brain‐Kidney Axis Dysfunction in Intracerebral Hemorrhage: Mechanisms and Interventions
Chen, Y., Guo, R., Wang, Y., Zhao, Z., Chen, L., Zhang, Y., Xu, F., Wei, L., Chen, G., Yang, G., et al. (2026) · The FASEB Journal · doi:10.1096/fj.202601498rrr
“Renin converts angiotensinogen to angiotensin I, then to Ang II via angiotensin-converting enzyme (ACE) [62, 83].”
InfluentialLuo, C., Lin, K., Chen, R., Ye, K., Shi, S., Huang, M., & Xu, Y. (2026) · Healthcare · doi:10.3390/healthcare14203438
“…promotes renal vasoconstriction, glomerular hyperfiltration injury, podocyte foot process effacement, and renal microvascular endothelial damage [46]; concurrently, sympathetic over-stimulation triggers excessive renin–angiotensin–aldosterone system (RAAS) activation, further amplifying…”
Herat, L. Y., Balmer, L. A., Lavender, N., Rozario, T., & Schlaich, M. P. (2026) · Current Opinion in Physiology · doi:10.1016/j.cophys.2026.101004
Desai, Y., Ghaner, A., Galo, J., German, C. A., Bernardo, N. L., Taylor, A., Hashim, H. D., Waksman, R., & Case, B. C. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.110865
Metadata
- Authors
- Kaur, J., Young, B., & Fadel, P.
- Affiliations
- The University of Texas at Arlington (US)
- Corresponding author
- Fadel, Paul
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-08-02
- Volume
- 18
- Issue
- 8
- Pages
- 1682
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5578072
- OpenAlex
- W2741868536
- Cited by
- 168
- References
- 156
- Citations by year
- 2026: 19 · 2025: 27 · 2024: 25 · 2023: 14 · 2022: 17 · 2021: 23 · 2020: 16 · 2019: 16 · 2018: 9 · 2017: 1
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (NIH R01 HL127071)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
- Keywords
- chronic kidney disease, sympathetic nervous system, sympathoexcitation, sympathetic activity, hypertension, cardiovascular risk, chronic kidney disease progression, cardiovascular mortality, therapeutic target
- MeSH terms
- Animals, Humans, Hypertension, Renal, Sympathetic Nervous System, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.